Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study

---

Atıf İçin Kopyala

KARADAĞ Ö., DALKILIÇ H. E., AYAN G., KÜÇÜKŞAHİN O., KAŞİFOĞLU T., Yilmaz N., ...Daha Fazla

CLINICAL RHEUMATOLOGY, cilt.41, sa.1, ss.85-94, 2022 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 41 Sayı: 1
• Basım Tarihi: 2022
• Doi Numarası: 10.1007/s10067-021-05893-3
• Dergi Adı: CLINICAL RHEUMATOLOGY
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
• Sayfa Sayıları: ss.85-94
• Anahtar Kelimeler: Anti-TNF, ACR20/50/70, DAPSA28, DAS28, Psoriatic arthritis, Work disability, CERTOLIZUMAB PEGOL, CLINICAL-RESPONSE, DISEASE-ACTIVITY, DOUBLE-BLIND, PHASE-III, GOLIMUMAB, SAFETY, TRIAL, MULTICENTER, ETANERCEPT
• Akdeniz Üniversitesi Adresli: Evet

Özet

Objectives To understand change in work productivity, activity impairment, quality of life (QoL), and disease activity in patients with psoriatic arthritis (PsA) receiving anti-tumor necrosis factor (anti-TNF) treatment.